GP2017: An Adalimumab Biosimilar
- 236 Downloads
GP2017 (adalimumab) is a biosimilar anti-TNF-α antibody. It is approved in the EU for use in all indications for which reference adalimumab is approved. GP2017 has similar physicochemical and functional properties to those of reference adalimumab, and the pharmacokinetic similarity of the agent has been shown in healthy male volunteers. GP2017 demonstrated clinical efficacy equivalent to that of reference adalimumab in patients with moderate to severe plaque psoriasis or rheumatoid arthritis; the tolerability, safety and immunogenicity profiles of the two agents were also similar. Multiple switching between GP2017 and reference adalimumab (up to four times) had no impact on efficacy, tolerability or immunogenicity. The role of reference adalimumab in the management of autoimmune inflammatory conditions is well established and GP2017 provides an effective biosimilar alternative for patients requiring adalimumab therapy.
Compliance with Ethical Standards
Conflict of interest
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of GP2017 was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit. Young-A Heo is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.European Medicines Agency. Hyrimoz: EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 30 Aug 2018.
- 2.European Medicines Agency. Hefiya: EU summary of product characteristics. 2018. http://www.ema.europa.eu/. Accessed 8 Oct 2018.
- 3.European Medicines Agency. Halimatoz: EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 8 Sept 2018.
- 4.Abbvie Inc. Humira® (adalimumab) injection, for subcutaneous use: US prescribing information. 2018. http://www.fda.gov. Accessed 5 Oct 2018.
- 5.European Medicines Agency. Humira (adalimumab): EU summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 5 Oct 2018.
- 6.Schiestl M, Roesli C. Development and analytical characterization of GP2017: a proposed adalimumab biosimilar [abstract no. 627]. Am J Gastroenterol. 2016;111(Suppl 1):S289.Google Scholar
- 7.European Medicines Agency. Hyrimoz (adalimumab): EMA assessment report 2018. http://www.ema.europa.eu. Accessed 31 Aug 2018.
- 10.Blauvelt A, Lacour JP, Fowler JF, et al. Long-term efficacy, safety, and immunogenicity data from a phase III confirmatory study comparing GP2017, a proposed biosimilar, with reference adalimumab [abstract no. 751]. Am J Gastroenterol. 2017;112(Suppl 1):S419.Google Scholar
- 11.Wiland P, Jeka S, Dokoupilova E, et al. A randomized, double-blind, parallel-group, multicenter study to compare the efficacy, safety and immunogenicity of a proposed adalimumab biosimilar (GP2017) with reference adalimumab in patients with moderate-to-severe active rheumatoid arthritis [abstract no. 1936]. Arthritis Rheumatol. 2018;70(Suppl 10).Google Scholar
- 12.Jauch-Lembach J, Skerjanec A, Haliduola H, et al. Randomized, double-blind, single-dose, three-arm parallel trial to determine the pharmacokinetics and safety of GP2017, EU-and US-adalimumab in healthy male subjects [abstract no. 2443]. Arthritis Rheumatol. 2017;69(Suppl 10).Google Scholar